NLRP3 and colorectal carcinoma: AOM/DSS-treated mice carrying this mutation are more resistant to both intestinal inflammation and CRC development, which mechanistically, is thought to occur by mutant Nlrp3 gain-of-function processes resulting in increased IL-1β-dependent secretion of antimicrobial peptides.